You Can Do Anything
Long-term survivor Jay Bozick carries the BRCA2 mutation, which has made newer treatments an option for his pancreatic cancer.
Taking Chances to Beat Pancreatic Cancer
With a family history of pancreatic cancer, Jay Bozick discovered he carries the BRCA2 mutation, which directed his treatment.
Urinary Tract Scans Lead to My Diagnosis
Ellen Robbins has the BRCA2 mutation, and that allowed her to participate in a clinical trial for her pancreatic cancer.
Roxanne Waling is a long-term survivor of pancreatic cancer, and she credits her integrative oncology team for helping her through.
When Helene Avraham-Katz was diagnosed with pancreatic cancer, she and her family made the decision to fight it with everything they could.
Steven Merlin and Davi D’Agostino Team Up to Help Others
Pancreatic cancer patient advocates Steven Merlin and Davi D’Agostino have joined to pool expertise and information for other patients.
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
The Butterfly Effect and Living Every Day to My Fullest
Because Helene Avraham-Katz has the BRCA2 mutation, certain chemotherapies work better and she is eligible for specific clinical trials.
BRCA Mutation Determines My Pancreatic Cancer Treatment
Chris Treubert started with one type of chemotherapy but when the results of genetic testing showed a BRCA mutation he changed treatment.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
A Second Opinion Makes the Difference
Irma Infante refused to give up after a stage IV pancreatic cancer diagnosis. She went for a second opinion and better treatment options.
Genetic Testing Leads Me to a PARP Inhibitor Trial
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.
A Genetic Mutation Aids My Treatment
Malcolm Robertson carries the BRCA2 mutation, so when he was diagnosed with pancreatic cancer, platinum-based chemo was part of his treatment.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
My Pancreatic Cancer Clinical Trial Journey
After starting pancreatic cancer treatment, Davi D’Agostino discovered she has the BRCA2 mutation, which made her eligible for a clinical trial.